Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02193568
Other study ID # OSU-12161
Secondary ID NCI-2014-01110
Status Completed
Phase Phase 4
First received
Last updated
Start date April 30, 2014
Est. completion date January 24, 2019

Study information

Verified date March 2019
Source Ohio State University Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized clinical trial studies light sedation compared with intubated general anesthesia (a loss of feeling and a complete loss of awareness that feels like a very deep sleep) in reducing complications and length of hospital stay in patients with brain cancer undergoing craniotomy. Craniotomy is an operation in which a piece of the skull is removed so doctors can remove a brain tumor or abnormal brain tissue. Light sedation allows patients to remain awake during their surgery, while intubated general anesthesia puts patients to sleep. Surgery complication rates may be reduced if intubated general anesthesia is avoided. Additionally, patients not receiving intubated general anesthesia tend to recover more quickly after surgery. It is not yet known whether light sedation is better at reducing complications and length of hospital stay compared to intubated general anesthesia.


Description:

PRIMARY OBJECTIVES:

I. To compare the overall hospital length of stay (LOS) in patients undergoing craniotomy with light sedation vs. general anesthesia.

SECONDARY OBJECTIVES:

I. To compare resource utilization between the two groups. II. To assess the frequency of post-operative delirium. III. To measure patient perceptions. IV. To track patient complications during hospital stay - nausea/vomiting, pain, hematology/lab stability, hemodynamic stability.

V. To track re-admission and extended hospital stay rates. VI. To compare cost of both approaches.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive light sedation (awake) and undergo craniotomy.

ARM II: Patients receive intubated general anesthesia and undergo craniotomy.

After completion of study, patients are followed up at 1month and 1 year.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date January 24, 2019
Est. primary completion date October 8, 2016
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria:

- Non-pregnant females

- Elective craniotomy for supratentorial brain tumors

- Primary brain cancer (presumed gliomas with no radiographic or clinical evidence of metastatic disease to the brain)

- First craniotomy

- American Society of Anesthesiologists (ASA) I-III

- Body mass index (BMI) < 35

Exclusion Criteria:

- Posterior fossa tumor/approach for tumor resection requiring the prone position

- Traumatic lesions/hematomas

- Emergency case

- Systemic disease burden with metastatic tumor to the brain

- Presence of medical co-morbidities, which, in the opinion of the investigator complicates the surgical procedure or would require additional hospital stay

- Necessity of awake procedure requiring intraoperative participation of patient due to the presence of the lesion in eloquent brain areas

- Prisoners

- Pregnant women

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Arm I (light sedation)
If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.
Arm II (intubated general anesthesia)
Receive intubated general anesthesia
Arm II (intubated general anesthesia)
Undergo craniotomy
Other:
Arm II (intubated general anesthesia)
Ancillary studies
Procedure:
Arm I (light sedation)
Undergo craniotomy
Other:
Arm I (light sedation)
Ancillary studies

Locations

Country Name City State
United States Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
Ohio State University Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Compare overall hospital length of stay for patients in each of 2 arms Will be summarized for each arm and compared between light sedation and general anesthesia arm using two-sample test. Regression model will also be used to study the association between the length of stay and the type of anesthesia with potential confounder variables. Up to 1 year
Secondary Compare resource utilization between two groups Compare costs of hospital stay, anesthesia, and surgery Up to 1 year
Secondary Assess the frequency of post-operative delirium Post-operative delirium will be assessed using the Memorial Delirium Assessment Scale (MDAS); a tool developed to measure the severity of delirium and reflects the main diagnostic criteria and symptoms of delirium. The MDAS is structured as a ten-item, four-point clinician-rated scale (possible range, 0-30) designed to quantify the severity of delirium in medically ill patients. A score of 13 has been recommended by the original authors as a cutoff for establishing the diagnosis of delirium. Up to 1 year
Secondary Measure patient perceptions Will be measured by asking patients about their overall positive experiences, if they understood rationale behind non-intubated craniotomy; necessary to improve outcomes and minimize complications; self-protection/preservation, if they appreciated receiving information before surgery to help them make informed decisions, and their trust in the surgeon via survey to be conducted at the conclusion of the inpatient stay, before hospital discharge Up to 1 year
Secondary Track patient complications during hospital stay Track patient nausea/vomiting, pain, hematology/lab stability, hemodynamic stability Up to 1 year
Secondary Track re-admission and extended hospital stay rates Tracking will be done using the EMR and follow-up calls Up to 1 year from the date of surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02259218 - Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
Recruiting NCT04553341 - Induction of Cortical Plasticity N/A
Recruiting NCT01806155 - Prevalence of Post-craniotomy Headache in Siriraj Hospital N/A
Completed NCT03525080 - Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors N/A
Completed NCT01738646 - Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Phase 2
Completed NCT00379080 - Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma Phase 1/Phase 2
Completed NCT01024907 - Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Phase 1/Phase 2
Completed NCT01172964 - A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas Phase 1

External Links